TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27655522
Drug: Highly dosed
Normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly dosed folic acid (5 mg/day) (control group)
Study: 12888156
Drug: Anthracycline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline treatment
Study: 18273636
Drug: Fast-track treatment
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track treatment arm
Study: 22812672
Drug: IV levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV levofloxacin (500 mg q24h)
Study: 7531132
Drug: 2 treatments
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 treatments with 7.2 Gy at a 3-week interval (Group 2)
Study: 23715170
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 75 mg per day
Study: 20736941
Drug: Zinc salt
Normalized name: ditiocarb, zinc salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc salt and proton pump inhibitor (PPI)
Study: 19750306
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 15 mL of 0.125% ropivacaine (EA group)
Study: 1756692
Drug: Amidotrizoic acid
Normalized name: Amidotrizoic acid
DrugBank: Diatrizoate (DB00271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amidotrizoic acid (2.1 osmol/kg; mean dosage 166 +/- 68 or 2.2 +/- 1.1 ml/kg)
Study: 10214426
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (no treatment)
Study: 25858957
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV)
Study: 20716629
Drug: Post-treatment Ki-67
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment Ki-67 in the top quartile (≥30%)
Study: 19431219
Drug: TBE parameter
Normalized name: TBE vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE parameter (height at 1 min) post-treatment
Study: 11391583
Drug: Paclitaxel 90
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m2 and estramustine 900 mg/m2 (Cohort IV)
Study: 12660683
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg
Study: 30572548
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) combined with conventional rehabilitation therapy
Study: 8792262
Drug: Peer-mediated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peer-mediated intervention with normally developing peers, matched by sex and age, details on dosage and duration not available.
Study: 2643914
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of zidovudine
Study: 20530280
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of trastuzumab treatment
Study: 16189633
Drug: Intravenous OCT
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous OCT
Study: 1632114
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pirenzepine i.v.
Study: 25415108
Drug: Levobupivacaine (0.5%)
Normalized name: levobupivacaine 0.5 MG/ML
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine (0.5%) infusion at 2 ml/hour for 48 hours
Study: 21303633
Drug: Dual nostril
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual nostril administration of 75 U insulin
Study: 21303633
Drug: Dual nostril
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual nostril administration of 100 U insulin
Study: 2904898
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (antibiotic treatment)
Study: 26091817
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) using right unilateral or bitemporal electrode placement and brief or ultrabrief pulse width, administered 3 times per week.
Study: 1330574
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril
Study: 9039333
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (2 IU/m2 per day)
Study: 29371246
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg daily folic acid + 10 mg enalapril
Study: 15132403
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy
Study: 12004993
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (88 microg [2 puffs of 44 microg] twice daily)
Study: 31376619
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine in Apidra®
Study: 27592038
Drug: Cervical physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical physical therapy for 6 weeks (12 sessions)
Study: 8520793
Drug: Furosemide aerosol
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide aerosol (10 mg)
Study: 8520793
Drug: Furosemide treatment
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide treatment over 1 month
Study: 6176320
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy
Study: 19384690
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies
Study: 6797571
Drug: Aminoglutethimide 250
Normalized name: aminoglutethimide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide 250 mg by mouth four times daily with hydrocortisone 20 mg twice daily
Study: 10022422
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 12 months
Study: 11299099
Drug: Semi-quantitative food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-quantitative food frequency questionnaire (FFQ) administered at baseline (FFQ1) and repeated 1 year later (FFQ2)
Study: 9100428
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg and 0.8 mg/kg
Study: 3296735
Drug: Methylprednisolone 120
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 120 mg
Study: 25189856
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol (0.45 g/kg)
Study: 1306633
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches
Study: 10737581
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenously at induction of anesthesia
Study: 9014625
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg kg‐1 followed by a 9‐mg kg‐1 h‐1 continuous infusion
Study: 1515878
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (TBI dose 12 Gy, no anthracyclines)
Study: 9156817
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin (UW) solution
Study: 8220156
Drug: Cytarabine 200
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 200 mg/m2/day by continuous infusion for seven days
Study: 8220156
Drug: Cytarabine 500
Normalized name: CYTARABINE 500MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine 500 mg/m2 every 12 hours for 12 doses (intermediate-dose)
Study: 22250997
Drug: Early childhood
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early childhood education treatment
Study: 12660683
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg
Study: 23132800
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin)
Study: 1286486
Drug: Diclofenac 150
Normalized name: diclofenac sodium 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 150 mg/day
Study: 6621617
Drug: BAY h
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL GEL [Loews Portofino Bay Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY h 4502 (bifonazole) 1% cream/lotion applied once daily for 14 days
Study: 9281301
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation of isosorbide dinitrate
Study: 8143451
Drug: Progesterone 100
Normalized name: progesterone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 100 mg
Study: 27924798
Drug: Sulfate-rich mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfate-rich mineral water (1 l/day for 3 weeks)
Study: 15028553
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (C)
Study: 10199756
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog alone (nafarelin acetate; 200 microg, intranasally, twice daily)
Study: 8849298
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (Funazol)
Study: 29884405
Drug: Subretinal transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal transplantation of up to 200,000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks
Study: 11372002
Drug: Bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg/day
Study: 28407999
Drug: Spacing strategy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spacing strategy (TNF-blocker injection spacing)
Study: 15571316
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg once daily for 14 days
Study: 11510874
Drug: Heat-induced dehydration
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heat-induced dehydration after coffee consumption (caffeine 4.9 mg/kg, 3-4 cups)
Study: 30737932
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment with good quality root filling and good quality crown restoration (GE + GR)
Study: 23801357
Drug: Ponatinib 15
Normalized name: PONATinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 15 mg with ketoconazole 400 mg daily for 5 days
Study: 28052451
Drug: Nadroparin infusion
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin infusion (loading dose of 35 IU/kg and continuous infusion of 10 IU/kg per hour for 6 hours)
Study: 371903
Drug: Calcium carbimide
Normalized name: calcium carbimide
DrugBank: Calcium carbimide (DB09116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbimide (CC) 0.7 mg/kg
Study: 31187863
Drug: DHA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA + AA (200 mg each)
Study: 6754416
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray (long-term use for more than two years)
Study: 30942964
Drug: No-tablet control
Normalized name: caffeine Oral Tablet [No Doz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-tablet control
Study: 1667511
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose 250 ml
Study: 22379116
Drug: Unacylated ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unacylated ghrelin (UAG) infusion (1.0 μg/kg per h)
Study: 25864745
Drug: Food Supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food Supplement (FS) alone
Study: 25864745
Drug: Thyroid hormones
Normalized name: Thyroid hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormones alone
Study: 15298427
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (30 mg/kg)
Study: 16504873
Drug: 2-session treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-session treatment (calcium hydroxide as an intracanal dressing)
Study: 3044007
Drug: Maprotiline 50
Normalized name: maprotiline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 50 mg
Study: 2946975
Drug: Maprotiline 75
Normalized name: maprotiline 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 75 mg
Study: 1103916
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diazepam 10 mg
Study: 1103916
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration into the deltoid muscle of diazepam 10 mg
Study: 20615781
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol (group A)
Study: 8806288
Drug: SPf66 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 malaria vaccine
Study: 30808670
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase injection
Study: 21899741
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g cinnamon
Study: 11256241
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg orally every 12 hours for 7 days
Study: 31735178
Drug: Temporal fascia
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporal fascia graft plus platelet-rich fibrin therapy
Study: 8417172
Drug: Ribavirin 800
Normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 800 mg daily
Study: 8417172
Drug: Ribavirin 600
Normalized name: ribavirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 600 mg daily
Study: 27599663
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab 162 mg every week
Study: 27599663
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab 162 mg every 2 weeks
Study: 27599663
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab 8 mg/kg every 4 weeks
Study: 9202914
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Study: 19223621
Drug: ST-246 administered
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 administered at 10 mg/kg/day for 14 days
Study: 19223621
Drug: ST-246 administered
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 administered at 3 mg/kg to 100 mg/kg once a day for 14 days
Study: 18928104
Drug: Rukang Tablet
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rukang Tablet (RKT)
Study: 9679845
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate powder (50 microg or 100 microg twice daily)
Study: 28051240
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of montelukast, azithromycin and bronchodilators or glucocorticoid
Study: 27687537
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss + 2000IU oral vitamin D3/day
Study: 17134770
Drug: Trimethazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethazidine (TMZ) 20 mg, tds
Study: 28120446
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg
Study: 28170104
Drug: Adapted mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapted mindfulness intervention plus treatment as usual (n = 20)
Study: 26329790
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg (day 3)
Study: 27229470
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection and Lidocaine (IS)
Study: 12810472
Drug: No therapeutic
Normalized name: Gel, Multi Ingredient Topical application Gel/Jelly [AVEENO THERAPEUTIC SHAVE GEL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapeutic treatment
Study: 31223099
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion (10 h) of Zn (100 μmol)
Study: 31223099
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion (1 h) of Mn (1000 nmol)
Study: 15313860
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone sodium phosphate (1 mg/kg)
Study: 7051913
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of elemental zinc as zinc acetate (10 patients)
Study: 22893628
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously every 4 weeks
Study: 18077134
Drug: 0 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/d of supplemental Zn (placebo)
Study: 2112080
Drug: Hungarian-made levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hungarian-made levonorgestrel tablets (0.75 mg)
Study: 20210680
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg twice daily
Study: 20210680
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg twice daily
Study: 20357371
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 2.0 units/kg
Study: 20357371
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 0.5 units/kg
Study: 31304600
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose regimen (1500 IU anti-D at 28 weeks)
Study: 18804142
Drug: Formulation F1
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation F1 (vehicle)
Study: 18804142
Drug: Formulation F4
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation F4 (combination of vitamins and SCE)
Study: 375121
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg apomorphine s.c. for 15 days
Study: 24360050
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative anesthetic
Study: 19783713
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 1000 mg with pantoprazole 40 mg twice daily